Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.72 |
| ▸ | CRHBP | P24387 | 2/20 | 0.70 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | CASP5 | P51878 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788921 | 0.84 | CRHBP (0.96) | HRH4CRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL2168885 | 0.83 | HRH4 (0.75) | HRH4HRH3 | |
| SCHEMBL24313224 | 0.82 | CRHBP (1.00) | HRH4CRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL6600071 | 0.82 | CRHBP (1.00) | HRH4CRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL655533 | 0.82 | HRH4 (0.77) | HRH4CRHBPCRHR2SMN1; SMN2HRH3 | |
| SCHEMBL14538233 | 0.82 | CASP1 (0.53) | HRH4CRHBPCRHR2SMN1; SMN2HRH3 | |
| SCHEMBL30376883 | 0.82 | CASP1 (0.53) | HRH4CRHBPCRHR2SMN1; SMN2HRH3 | |
| SCHEMBL1616232 | 0.81 | HRH4 (0.72) | HRH4CRHBPCRHR2SMN1; SMN2MAPT | |
| SCHEMBL8565532 | 0.79 | HRH4 (0.72) | HRH4SMN1; SMN2MAPTHRH3CASP1 | |
| SCHEMBL5789932 | 0.79 | CRHBP (1.00) | HRH4CRHBPCRHR2SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-8716475-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | disclosed |
| US-4980350-A | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO., INC. (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0200968-B1 | SUCCINIMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885CRHBP 1702/4885CRHR2 1053/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HRH4 1/4885CRHBP 1789/4885CRHR2 1230/4885 |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885CRHBP 1702/4885CRHR2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.